TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10226978
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (nCPAP therapy)
Study: 8767921
Drug: nitroglycerine-patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: nitroglycerine-patches
Study: 1505149
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg diazepam
Study: 31349876
Drug: Secukinumab (anti-IL-17A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab (anti-IL-17A antibody) administered over 24 weeks
Study: 25231697
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI) therapy for 6 months
Study: 18095198
Drug: Fentanyl (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (0.7 microg/kg loading, 10 microg bolus dose with 5 minutes lockout time)
Study: 18095198
Drug: Remifentanil (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.3 microg/kg loading, 20 microg bolus dose with 3 minutes lockout time)
Study: 18095198
Drug: Control (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (saline solution without analgesic)
Study: 16001776
Drug: Angiotensin converting
Normalized name: Angiotensin converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists, and beta‐adrenergic blockers
Study: 15071276
Drug: Prophylactic implantable
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic implantable cardioverter defibrillator (ICD) therapy
Study: 9925529
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mefloquine (25 mg/kg) on day 2 with food
Study: 9925529
Drug: Split dose
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split dose of mefloquine (15 mg/kg on day 2 and 10 mg/kg on day 3) with food
Study: 9925529
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mefloquine (25 mg/kg) on day 0 without food
Study: 9925529
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of mefloquine (25 mg/kg) on day 2 without food
Study: 7789044
Drug: Intraperitoneal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal insulin delivery
Study: 6236952
Drug: Desogestrel 0.125
Normalized name: desogestrel 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel 0.125 mg
Study: 6236952
Drug: Desogestrel 0.250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel 0.250 mg
Study: 6236952
Drug: Desogestrel 0.500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desogestrel 0.500 mg
Study: 6236952
Drug: Lynestrenol 5
Normalized name: lynestrenol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lynestrenol 5 mg
Study: 30232658
Drug: Vasopressin–Steroids–Epinephrine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasopressin–Steroids–Epinephrine combination
Study: 23836299
Drug: Rehabilitation programme
Normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation programme including exercises and cognitive-behavioural therapy
Study: 12153599
Drug: Oestrogen plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen plus methyltestosterone (1.25 mg esterified oestrogen and 2.5 mg methyltestosterone)
Study: 12153599
Drug: Oestrogen only
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen only (1.25 mg esterified oestrogen)
Study: 2145499
Drug: 5% tea-tree
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% tea-tree oil gel
Study: 28431003
Drug: High-dose BMCs
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose BMCs (hiBMCs)
Study: 28431003
Drug: Low-dose BMCs
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose BMCs (loBMCs)
Study: 28431003
Drug: Irradiated high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiated high-dose BMCs (irradiated hiBMCs)
Study: 28431003
Drug: Irradiated low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irradiated low-dose BMCs (irradiated loBMCs)
Study: 15047458
Drug: No anti-anaemic
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anti-anaemic treatment
Study: 18353329
Drug: GnRHa treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRHa treatment
Study: 8770484
Drug: Anesthesia infusion
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anesthesia infusion sleeve (AIS)
Study: 2894215
Drug: Ketanserin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (mean daily dose 71 mg)
Study: 18677023
Drug: Subcutaneous growth
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous growth hormone (GH) starting dose 2 microg/kg/d, increased to maximum dose of 6 microg/kg/d for 18 months.
Study: 15933559
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) 50 mg/m for infants >28 days of age
Study: 15933559
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) 25 mg/m for infants < or =28 days of age, escalated to 50 mg/m
Study: 9495218
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) treatment
Study: 15933559
Drug: Didanosine (ddI)
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Didanosine (ddI) treatment
Study: 10392222
Drug: Instillation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instillation of 5 mL of normal saline before endotracheal suctioning
Study: 8546551
Drug: Sulfamethoxazole-trimethoprim (double-strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfamethoxazole-trimethoprim (double-strength tablet three times a week)
Study: 8546551
Drug: Aerosolized pentamidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosolized pentamidine (dose not specified)
Study: 8546551
Drug: Oral regimens
Normalized name: aspirin Oral Tablet [Anacin Aspirin Regimen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral regimens (compared to aerosolized pentamidine)
Study: 28600725
Drug: Oxycodone DETERx
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone DETERx
Study: 26923083
Drug: Quinvaxem in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinvaxem in cPAD injection system
Study: 26923083
Drug: Quinvaxem in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinvaxem in single-dose vial
Study: 26923083
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (cPAD and single-dose vial)
Study: 19080533
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with salmeterol/fluticasone (50/250 microg) twice daily and tiotropium 18 microg once daily (n = 33, M/F: 23/10)
Study: 19080533
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with salmeterol/fluticasone and tiotropium
Study: 19080533
Drug: Salmeterol/fluticasone (50/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone (50/250 microg) twice daily (n = 32, M/F: 24/8)
Study: 19080533
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg once daily (n = 32, M/F: 23/9)
Study: 12118027
Drug: PVI 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PVI 5-FU (300 mg/m²/d for a maximum of 24 weeks)
Study: 12118027
Drug: PVI 5-FU
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PVI 5-FU plus MMC (7 mg/m² every 6 weeks for four courses)
Study: 2303688
Drug: Emergency sclerotherapy
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emergency sclerotherapy with larger volumes of sclerosant (mean of 26 ml)
Study: 7374618
Drug: oxygen-multistep-therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: oxygen-multistep-therapy
Study: 27919633
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose inactivated influenza vaccine (HD IIV)
Study: 27919633
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose inactivated influenza vaccine (SD IIV)
Study: 26391700
Drug: Cyproterone acetate/ethinyloestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate/ethinyloestradiol with metformin
Study: 26391700
Drug: Cyproterone acetate/ethinyloestradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate/ethinyloestradiol without metformin
Study: 26391700
Drug: PCOS without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCOS without insulin resistance (IR)
Study: 11881062
Drug: Lisinopril (ACE-I)
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril (ACE-I)
Study: 11881062
Drug: Both drugs
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both drugs (Candesartan cilexetil and Lisinopril)
Study: 3043355
Drug: roxithromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin (150 mg bd)
Study: 3043354
Drug: erythromycin ethylsuccinate
Normalized name: Erythromycin Ethylsuccinate
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: erythromycin ethylsuccinate (1 g bd)
Study: 31544377
Drug: Fresh leonurus
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fresh leonurus japonicus capsule, 0.8 g, 3 times a day for 7 days, for 3 courses until embryo transfer.
Study: 23648075
Drug: Intravenous supply
Normalized name: SUPPLY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous supply of omega-3 PUFAs (EPA and DHA)
Study: 21614496
Drug: Metformin (850
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (850 mg) twice daily for 3 months followed by CC/HMG/HCG for 3 months
Study: 21614496
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 3 months followed by CC/HMG/HCG for 3 months
Study: 18221256
Drug: Daclizumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab (1 mg/kg infusion 2 hours before transplantation and then every 14 days for four more doses)
Study: 18221256
Drug: Tacrolimus-based therapy
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus-based therapy without daclizumab (historical control group)
Study: 17722304
Drug: Topical 10%
Normalized name: urea topical 10% topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 10% vitamin C derivative (VC-PMG)
Study: 17722304
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% vitamin E
Study: 12923149
Drug: Hysteroscopic adhesiolysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hysteroscopic adhesiolysis plus intrauterine application of ACP gel (10 ml)
Study: 9123741
Drug: Neoadjuvant androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant androgen suppression prior to radiation therapy
Study: 28988549
Drug: TAU (treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAU (treatment as usual) plus low‐intensity CBT‐Music (treatment)
Study: 18411039
Drug: Cochrane reviews
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochrane reviews (drug interventions)
Study: 18411039
Drug: DARE reviews
Normalized name: Darexaban
DrugBank: Darexaban (DB12289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DARE reviews (drug interventions)
Study: 12913326
Drug: Mixture containing
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture containing acetyl‐L‐carnitine (ALC), polyunsaturated fatty acids (PUFAs), coenzyme Q10 (CoQ10) and vitamin E
Study: 10873918
Drug: Sequential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential treatment (adding a selective serotonin reuptake inhibitor)
Study: 9199588
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B Ortho toothbrushes
Study: 9199588
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B Plus 35 toothbrushes
Study: 1549027
Drug: Propranolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (10 mg, oral dose)
Study: 4077364
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg metoprolol (i.v.)
Study: 4077364
Drug: 0.30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30 mg/kg metoprolol (i.v.)
Study: 4077364
Drug: Chronic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic treatment with slow-release metoprolol (1 X 200 mg/day for 4 weeks)
Study: 30376962
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (10 mg/kg)
Study: 27153745
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg E4/DRSP
Study: 27153745
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg E4/LNG
Study: 26891216
Drug: Black raspberry
Normalized name: BLACK RASPBERRY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black raspberry (750 mg/day)
Study: 22464728
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual including occupational therapy (TAU)
Study: 22166634
Drug: Tailored loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored loading dosage of clopidogrel
Study: 22166634
Drug: Rational loading
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rational loading dosage of clopidogrel
Study: 11286312
Drug: Extended treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended treatment with dalteparin for 3 months after initial treatment
Study: 25359642
Drug: Invasive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive therapy
Study: 9412548
Drug: Albuterol 400
Normalized name: albuterol 400 MCG/ACTUAT Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 400 micrograms
Study: 1829368
Drug: Bendrofluazide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendrofluazide (5 mg once daily)
Study: 30317262
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 10mg of 0.5% hyperbaric bupivacaine (Group A)
Study: 30317262
Drug: Height and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Height and weight-adjusted dose of 0.5% hyperbaric bupivacaine (Group B)
Study: 30768407
Drug: Sertraline for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline for 12 weeks
Study: 18837604
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (group and individual)
Study: 14613676
Drug: 5-HT(2) antagonists
Normalized name: 5-HT
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT(2) antagonists (clozapine or olanzapine)
Study: 1466849
Drug: Dapsone (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone (100mg orally twice weekly)
Study: 1466849
Drug: Pentamidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentamidine (400 mg nebulized monthly)
Study: 31535100
Drug: 11-mm-long implants
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-mm-long implants combined with maxillary sinus floor elevation
Study: 31535100
Drug: 6-mm-long implants
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-mm-long implants without any grafting
Study: 28522762
Drug: Postmeal exercise
Normalized name: OATMEAL
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postmeal exercise with metformin
Study: 28522762
Drug: Metformin/sedentary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/sedentary
Study: 28522762
Drug: Metformin/exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin/exercise
Study: 18675519
Drug: Imipramine (1mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (1mg/kg daily, max 100mg)
Study: 18675519
Drug: Fluoxetine (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (5mg for >40kg, 10mg for 40-60kg, 20mg for >60kg)
Study: 15970897
Drug: Contraceptive patch
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive patch (ethinyl estradiol [EE] 20 microg/d and norelgestromin 150 microg/d)
Study: 15970897
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (EE 35 mug and norgestimate 250 microg)
Study: 12878917
Drug: Naltrexone and
Normalized name: Naltrexone and Bupropion Hydrochlorides Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone and acamprosate (16 weeks of active treatment)
Study: 12878917
Drug: No-pill psychotherapy-alone
Normalized name: No Doz Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-pill psychotherapy-alone condition
Study: 10474019
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day ipriflavone
Study: 10474019
Drug: 0.8 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g/day calcium lactate
Study: 8695365
Drug: Gemcitabine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine administered as a 24 h infusion at a maximum tolerated dose (MTD) of 180 mg m‐2 on days 0, 7, and 14, repeated every 28 days.
Study: 8695365
Drug: Gemcitabine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine administered as a 24 h infusion at various dose levels (10, 20, 40, 80, 120, 180, and 210 mg m‐2).
Study: 8695365
Drug: Maximum tolerated
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum tolerated dose of gemcitabine.
Study: 1878329
Drug: 2% solution
Normalized name: Lidomar 2% Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% solution of mineralizing agent and 0.2% NaF solution
Study: 1878329
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and 0.2% NaF solutions
Study: 11216430
Drug: Minilaparoscopy (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minilaparoscopy (ML)
Study: 19789191
Drug: Intravenous low
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous low dose dexamethasone (4 mg initial dose, followed by 2 mg every 8 hours for 24 hours)
Study: 15036491
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (E2V) and medroxyprogesterone acetate (MPA) treatment for 12 or 14 days with combinations of 1 mg or 2 mg E2V and 2.5 mg or 5 mg MPA.
Study: 11485531
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (122 patients)
Study: 8047805
Drug: Pivmecillinam, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pivmecillinam, 50 mg/kg.day for 5 days
Study: 8047805
Drug: Nalidixic acid,
Normalized name: Nalidixic Acid, 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalidixic acid, 60 mg/kg.day for 5 days
Study: 30106530
Drug: Two-step 0.454%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-step 0.454% SnF₂ dentifrice and 3% H₂O₂ gel sequence
Study: 28942806
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care (low intensity, standard CBT, individually tailored treatment)
Study: 28942806
Drug: Single, empirically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, empirically validated cognitive-behavioral therapy (CBT) program
Study: 23589527
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion at 0.2 nmol kg(‐1) h(‐1)
Study: 23589527
Drug: Ghrelin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ghrelin infusion at 0.6 nmol kg(‐1) h(‐1)
Study: 18088076
Drug: Open donepezil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open donepezil treatment
Study: 8740617
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with no advanced preparation
Study: 1907422
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous nitroglycerin (33 micrograms/min)
Study: 1907422
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous nitroglycerin (133 micrograms/min)
Study: 30415593
Drug: Ocrelizumab 600
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 600 mg every 24 weeks for ⩾120 weeks
Study: 30415593
Drug: Ocrelizumab 600
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 600 mg
Study: 27835715
Drug: Adjunctive ziprasidone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive ziprasidone (escitalopram + ziprasidone, n = 71)
Study: 25727243
Drug: Forward leaning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forward leaning body posture with inhalation of 200 μgr salbutamol
Study: 25727243
Drug: Standard body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard body posture with inhalation of 200 μgr salbutamol
Study: 14617545
Drug: Right ventricular
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right ventricular pacing (RVP) patients with drug resistant heart failure (group B)
Study: 11198726
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg once daily for 7 days)